Meng Li, Wei Wenbin, Li Yanlong, Hui Xiaoying, Han Xiaodong, Shi Xiaobo
Beijing Tong Ren Hospital, Capital Medical University, Beijing, 100730, China.
Int Ophthalmol. 2015 Aug;35(4):487-93. doi: 10.1007/s10792-014-9974-0. Epub 2014 Jul 26.
To evaluate the efficacy of 25-ga pars plana vitrectomy (PPV) and 25-ga PPV combined with phacoemulsification surgery for managing ciliary block (malignant) glaucoma. The medical records of 11 eyes, in nine consecutive patients with malignant glaucoma were retrospectively reviewed to determine the efficacy of 25-ga PPV for alleviating this disease. All phakic eyes underwent phacoemulsification surgery during vitrectomy. Control of intraocular pressure (IOP), pre- and postoperative best-corrected visual acuity (BCVA), and development of intra- and postoperative complications were evaluated during follow-up. Malignant glaucoma was promptly resolved, and recurrence was not observed during a mean follow-up period of 12.7 ± 3.2 (range 6-18) months. The mean IOP decreased from 35.9 ± 2.9 mmHg, preoperatively, to 16.0 ± 1.4 mmHg, measured at last visit (P = 0.013). Although IOP control was achieved in all eyes after surgery, two eyes required long-term topical antiglaucoma medication. The mean logarithm of the minimum angle of resolution BCVA improved from +0.69 ± 0.11, preoperatively, to +0.29 ± 0.07, postoperatively (P = 0.027). No severe intraoperative complications were observed. Postoperative complications mostly occurred during the first week after surgery, including transient corneal edema and Descemet's membrane folds in three eyes, fibrotic exudation in 2, local iris posterior synechia in 1, and transient hypotony in 1, which were resolved spontaneously or with medication. The 25-ga PPV procedure seems to be safe and effective for treating malignant glaucoma. Combined vitrectomy with phacoemulsification surgery and a staged surgical approach may improve the success rate.
评估25G经平坦部玻璃体切除术(PPV)及25G PPV联合超声乳化手术治疗睫状环阻滞(恶性)青光眼的疗效。回顾性分析9例连续恶性青光眼患者11只眼的病历,以确定25G PPV缓解该病的疗效。所有有晶状体眼在玻璃体切除术中均接受了超声乳化手术。随访期间评估眼压(IOP)控制情况、术前和术后最佳矫正视力(BCVA)以及术中和术后并发症的发生情况。恶性青光眼迅速得到缓解,在平均12.7±3.2(范围6 - 18)个月的随访期内未观察到复发。平均眼压从术前的35.9±2.9 mmHg降至末次随访时测量的16.0±1.4 mmHg(P = 0.013)。虽然术后所有眼均实现了眼压控制,但有2只眼需要长期局部使用抗青光眼药物。最小分辨角BCVA的平均对数视力从术前的+0.69±0.11提高到术后的+0.29±0.07(P = 0.027)。未观察到严重的术中并发症。术后并发症大多发生在术后第一周,包括3只眼出现短暂性角膜水肿和后弹力层皱褶、2只眼出现纤维化渗出、1只眼出现局部虹膜后粘连、1只眼出现短暂性低眼压,这些并发症均自行缓解或经药物治疗后缓解。25G PPV手术治疗恶性青光眼似乎安全有效。玻璃体切除术联合超声乳化手术及分期手术方法可能会提高成功率。